CrowdStrike Holdings, Inc. – Consensus Indicates Potential 35.1% Upside

DirectorsTalk Interviews

CrowdStrike Holdings, Inc. found using ticker (CRWD) have now 32 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 385 and 193 calculating the average target price we see 242.94. Given that the stocks previous close was at 179.88 this would indicate that there is a potential upside of 35.1%. The 50 day MA is 186.04 and the 200 day moving average is 187.77. The company has a market cap of $44,293m. Visit the company website at: https://www.crowdstrike.com

The potential market cap would be $59,821m based on the market concensus.

CrowdStrike Holdings, Inc. provides cloud-delivered protection across endpoints and cloud workloads, identity, and data. It offers threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. The company primarily sells subscriptions to its Falcon platform and cloud modules through its direct sales team that leverages its network of channel partners. It serves customers worldwide. The company was incorporated in 2011 and is based in Austin, Texas.

Share on:

Latest Company News

Managers Back UK Income Stocks as Market Narrowness Signals Late-Cycle Conditions

UK income stocks seen as attractive amid market volatility, with managers highlighting undervaluation and narrowing global asset market conditions.

Cizzle Biotechnology secures up to £250,000 in additional funding

Cizzle Biotechnology has raised up to £250,000 through additional unsecured convertible loan notes issued to existing investor Frazer Lang.

Ferro-Alloy Resources raises £1.24m through share issue backed by key investors

Ferro-Alloy Resources has raised £1.24 million through the issue of 20.6 million new shares at 6p each, supported by strategic shareholder Vision Blue Resources and company directors.

Cizzle Biotechnology enters LOI with NHS partner to validate CIZ1B early cancer test

Cizzle Biotechnology has signed a Letter of Intent with a leading UK medical diagnostics provider working with the NHS to verify and validate its CIZ1B biomarker test for early lung

Drax secures low-carbon CfD for biomass units at Drax Power Station

Drax Group has signed a low-carbon dispatchable Contract for Difference (CfD) with the LCCC, covering all four biomass units at Drax Power Station from April 2027 to March 2031 at

Global Opportunities Trust posts September rise and 16.5% annual return

Global Opportunities Trust continues to pursue a disciplined, valuation-driven investment strategy, maintaining flexibility across asset classes and geographies while seeking long-term value for shareholders.

    Search

    Search